Health Canada Approves Skyrizi for Pediatric Plaque Psoriasis

Health Canada has approved SKYRIZI® (risankizumab) for children living with moderate to severe plaque psoriasis, extending the interleukin-23 inhibitor's (a biologic that blocks a key immune-signaling protein driving psoriasis) reach into a pediatric population with historically limited systemic options.

The regulator's decision, reported by Investing News Network, applies to pediatric patients with moderate to severe plaque psoriasis, the chronic inflammatory skin condition characterized by well-demarcated, scaly plaques. The source report does not specify the approved pediatric age range, the dosing regimen, or the filing pathway that supported the decision. Those omissions matter for clinicians weighing the approval against existing pediatric biologics.

What do we know about the approval?

• Health Canada approved SKYRIZI® for children with moderate to severe plaque psoriasis.
• The active agent is risankizumab, an interleukin-23 inhibitor already established in adult plaque psoriasis.
• The announcement was reported by Investing News Network; Health Canada issued the regulatory decision.

What the announcement does not state is equally relevant. There is no mention of PASI (Psoriasis Area and Severity Index, the standard 0-to-72 severity scale used in pivotal trials) response rates in children, no named pediatric study, and no detail on age eligibility. Any comparison to adult trial data, where risankizumab has shown high PASI 90 response rates, would be inference rather than reported fact. Pediatric efficacy and safety figures should be confirmed in the Canadian product monograph before counseling families.

Why a pediatric indication matters

Moderate to severe plaque psoriasis in children carries a durable burden: impaired quality of life, school and social disruption, and elevated lifetime risk of psoriatic arthritis. Systemic options for this cohort remain narrower than for adults, and approvals that widen the biologic formulary are clinically consequential even before headline efficacy numbers circulate.

A caveat follows the promise. Approval establishes eligibility, not access. Provincial formulary coverage, pediatric dosing availability, and remote-region supply will determine whether Canadian children actually receive the drug. None of those operational details appear in the announcement.

For dermatologists, the immediate practical step is to verify the approved age range and dosing in the official monograph, then assess which pediatric patients fail or intolerate current first-line biologics. Broader adoption will likely track with the release of pediatric-specific efficacy data and with provincial reimbursement decisions in the months ahead.